16-07-2025
Emcure and Sanofi India announce exclusive partnership to distribute oral anti-diabetic drugs in India
By Aditya Bhagchandani Published on July 16, 2025, 17:23 IST
Emcure Pharmaceuticals Ltd. and Sanofi India Ltd. (SIL) have announced an exclusive distribution and promotion agreement for Sanofi's oral anti-diabetic (OAD) products in India, effective immediately.
Under this partnership, Emcure will distribute and promote SIL's widely prescribed OAD brands, including Amaryl® and Cetapin®, leveraging its deep reach and network across India. Sanofi will continue to own and manufacture these products at its plants in India and globally.
The collaboration aims to expand access to trusted oral diabetes medicines to millions of patients across the country. Notably, there will be no employee transfers from Sanofi to Emcure as part of this deal.
Eric Mansion, GM Pharma Southeast Asia and India at Sanofi, said:
'Over 100 million Indians live with type 2 diabetes, and more than 60% have uncontrolled blood sugar levels. With Emcure's reach, we aim to unlock the full potential of our industry-leading OADs for patients and healthcare professionals.'
Satish Mehta, CEO & MD of Emcure, added:
'This partnership aligns with our mission to improve patient access to high-quality therapies and complements our existing diabetes portfolio, supporting better diabetes care nationwide.'
This alliance brings together Sanofi's strong brand portfolio and Emcure's extensive distribution network, strengthening both companies' presence in the critical diabetes care segment.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
